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Abstract
Vaccination, one of the most effective strategies to prevent infectious diseases, is the
administration of antigenic materials to stimulate an individual’s immune system to
develop adaptive immunity to a specific pathogen. Though it is so advantageous for
diseases control and prevention, vaccines still have some limitations. Nanotechnology is
an approach to prepare a novel biomedicine vaccine with the vaccine consumption and
side effects significantly decreased. Regulation is the most important criterion for the
development of nanovaccines. All marketing products have to meet the requirement of
regulation. The fast-track designation potentially aids in the development and expe‐
dites the review of nanovaccines that show promises in an unmet medical need. Here,
some successful nanovaccine products are introduced—Inflexal® V, Epaxal®, GardasilTM,
and CervarixTM have been widely used for the clinical applications, which are delivered
either in the form of virosomes or virus-like particles. Vaccines based on nanotechnolo‐
gy may overcome their original disadvantages and lead to the development of painless,
safer, and more effective products.
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1. Introduction
The terms vaccine and vaccination, derived from Variolae vaccinae (smallpox of the cow), were
devised by Edward Jenner to denote cowpox. Edward Jenner was an English doctor and
scientist who was the pioneer of smallpox vaccine, the first vaccine in the world. In 1796, Jenner
took pus from the hand of a milkmaid with cowpox and scratched it into the arm of an 8-year-
old boy. Six weeks later, he inoculated the boy with smallpox, afterwards observing that he
did not catch smallpox and no diseases followed [1, 2]. The boy was further challenged with
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various materials and again showed no signs and symptoms. In 1798, Jenner extended his
studies and reported that his vaccine was safe and could be transferred from arm-to-arm to
reduce dependence on uncertain supplies from infected cows [3]. In the 1880s, the second
generation of vaccines was introduced by Louis Pasteur who developed vaccines for chick‐
en cholera and anthrax [4]. In 1881, to honor Jenner, Louis Pasteur proposed that the terms
should be extended to cover the new protective inoculations then being developed [4]. From
the late nineteenth century,  vaccines were considered a matter  of  national  prestige,  and
vaccination is a compulsory policy in many countries [5]. In the twentieth century, several
successful vaccines were introduced such as those against diphtheria, measles, mumps, and
Type Definition Example
Inactivated Virulent microbes are previously
destroyed with chemicals, heat,
radiation, or antibiotics
Influenza vaccine, whole cell pertussis
vaccine, cholera vaccine, hepatitis A vaccine,
rabies vaccine, plague vaccine, inactivated
polio vaccine (IPV)
Attenuated Live microbes are cultivated under
conditions to disable their virulence,
or closely related but less dangerous
microbes are used to induce broad
immune responses
Yellow fever vaccine, shingles vaccine,
measles, mumps and rubella (MMR) vaccine, (1)typhoid
(Ty21a) vaccine, BCG vaccine, rotavirus vaccine,
live attenuated influenza vaccine (LAIV),
oral polio vaccine (OPV)
Toxoid Vaccines are made from inactivated
toxic compounds that cause illness
rather than microbes
Tetanus toxoid, diphtheria toxoid
Subunit Protein-based vaccine: A fragment of
protein creates an immune response,
rather than introducing inactivated
or attenuated microbes to an immune
system.
(2)Hepatitis B vaccine, (2)human
papillomavirus (HPV) vaccine
Polysaccharide vaccine: A
capsular polysaccharide antigen
is covalently attached to a
carrier protein and creates an immune
response.
(1)typhoid (Vi) vaccine,
(3)pneumococcus vaccine,
(4)meningococcus vaccine
Conjugate vaccine: Certain
pathogens have poorly immunogenic
polysaccharide outer coats. The
immune system recognizes the
polysaccharide as if it were a
protein antigen by linking
these outer coats to proteins
Haemophilus influenzae
type b (Hib) vaccine, (3)pneumococcus
vaccine, (4)meningococcus vaccine
Table 1. The major types of vaccines in the clinical application represent different strategies used to reduce the risk of
illness, while retaining the ability to induce beneficial immune responses.
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rubella.  During  this  period,  the  development  of  the  polio  vaccine  in  the  1950s  and the
eradication of smallpox around 1960s–1970s are great achievements. As vaccines had already
become more common, many people began taking them for granted.
A vaccine, an antigenic material, is a biological preparation that provides adaptive immuni‐
ty to a specific disease. The agent triggers immune responses to recognize the disease-causing
agent to destroy and remember it, so that the immune system can immediately recognize and
destroy the foreign agent once it invades into the body later. Inactivated microbes live
attenuated microbes, toxoids, subunits, or conjugates have been manufactured as vaccines and
employed to stimulate adaptive immune responses (Table 1). A monovalent (univalent)
vaccine is designed to immunize against a single antigen or microorganism such as measles
vaccine, while a multivalent (polyvalent) vaccine is designed to immunize against more than
one strain of the same microorganism or against more than one microorganism such as oral
polio vaccine (OPV), three in one (e.g., diphtheria-tetanus-pertussis, DTP) vaccine, etc.
Heterologous vaccines are pathogens of other animals that do not cause diseases or only cause
mild diseases in the organism being treated, such as the cowpox vaccine and the Bacillus
Calmette-Guérin (BCG) vaccine.
(1) Two types of typhoid vaccines are available: typhoid (Ty21a) vaccine (a live, attenuated
vaccine given by mouth) and typhoid (Vi) vaccine (a subunit vaccine given by injection). (2)
Current hepatitis B vaccine and human papillomavirus (HPV) vaccine may be produced by
recombinant DNA technology; therefore, they are sometimes called recombinant vaccines. (3)
Two types of pneumococcus vaccines given by injection are available: pneumococcal polysac‐
charide vaccine (PPSV) and pneumococcal conjugate vaccine (PCV). (4) Two types of menin‐
gococcus vaccines given by injection are available: meningococcal polysaccharide vaccine
(MPSV) and meningococcal conjugate vaccine (MCV).
It is well-known that prevention is better than cure for diseases control. Vaccination is the best
approach to prevent infectious diseases ahead of the incidence of diseases. Vaccination can
prevent or ameliorate morbidity from infection and result in herd immunity when a high
percentage of population has been vaccinated. For the past centuries, some diseases are
globally eradicated such as smallpox; some diseases are significantly controlled in much of the
world such as polio, measles, and tetanus through vaccines distribution. The effectiveness of
vaccination has been widely studied and verified such as the influenza vaccine [6], HPV
(Human papillomavirus) vaccine [7], and the shingles (chicken pox) vaccine [8], etc. In 2012,
the World Health Organization (WHO) reports that licensed vaccines are currently available
to contribute to the prevention and control of 25 infections. From the discovery of the related
pathogens, 25 infection have been effectively prevented using licensed vaccines; however,
vaccines remain elusive for many important diseases, such as the infections of Zika viruses,
cytomegaloviruses (CMV), hepatitis C viruses (HCV), Human immunodeficiency viruses
(HIV), severe acute respiratory syndrome (SARS) viruses, Ebola viruses, respiratory syncy‐
tial viruses (RSV), and malaria parasites Plasmodium, etc. (Figure 1). A vaccine is not only
conventionally prophylactic, hinting to prevent or alleviate the effects of a future infection, but
also may be therapeutic, vaccines against cancers are being investigated in recent research such
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as the HPV vaccine for cervical cancer, the BCG vaccine for bladder cancer [9] and colorectal
cancer [10].
Figure 1. Time line for the development of vaccines: 25 infections (  yellow column) have been reported by WHO
being prevented using licensed vaccines. However, some infections under research have no effective vaccines available
yet (  blank arrow column). *Varicella and herpes zoster: Varicella (chicken pox) and herpes zoster (shingles) are
diseases caused by varicella-zoster viruses (VZV) (one of the eight herpesviruses known to infect humans and verte‐
brates). **Influenza: A new version of the influenza vaccine is usually developed twice a year, because influenza virus‐
es mutate rapidly. ***Tuberculosis (TB): The Bacillus Calmette-Guérin (BCG) vaccine was originally developed from
Mycobacterium bovis found in cows; therefore, its efficacy against pulmonary TB appears to be variable in humans.
Abbreviations: Hepatitis (Hep.); Human papillomavirus (HPV); Human immunodeficiency virus (HIV); Japanese en‐
cephalitis (JE); Severe acute respiratory syndrome (SARS); Yellow fever (YF).
Vaccines have not only successfully reduced the incidence rate of many devastating diseases
to be always low but also prevented many infectious diseases from persistently bursting out.
At present, only few people have ever experienced the detrimental effects of many illnesses.
The two main advantages of vaccination are noted as follows:
1. Prevention in advance
Vaccination can result in lower morbidity and mortality rate as well as faster recovery
even though a partial, late, or weak immunity may only alleviate an infection. The early
protective efficacy of vaccination is primarily conferred by the induction of antigen-
specific antibodies. Vaccination can trigger adaptive immunity before contacting with the
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pathogen. Should a pathogen infect the body, there is no illness in that the immune
responses stimulated by vaccines continuously guard against the disease. The quality of
such antibody responses (avidity: a measure of the overall strength of an antigen–antibody
complex) has been identified as a determining factor of vaccines efficacy. However, there
is more to antibody-mediated protection than the peak of vaccine-induced antibody titers.
Vaccination stimulates both humoral and cell-mediated immunity of one’s own through‐
out the body. This kind of defensive response is usually safer, more effective and with
fewer side effects (e.g., inflammation, muscle aches, allergy, etc.) due to the active,
acquired and specific immunity is established. Through vaccination, humans can
eliminate or alleviate the attack of pathogens beforehand to avoid the suffering of diseases.
2. Immunity for long term
Vaccination stimulates adaptive immunity to create immunological memory that can
maintain in the body for a long period of time. Therefore, people will be protected from
the attack of diseases as long as these specific memory cells are still in the body. The disease
control or elimination requires the induction of protective immunity in a sufficient
proportion of the population. This is best achieved by vaccination programs capable of
inducing the long term protection (adaptive immunity) that contrasts to the quick but
short-lasting immune responses (innate immunity). Long-term immunity is conferred by
the maintenance of antigen-specific immune effectors and/or by the induction of im‐
mune memory cells that may be efficiently and rapidly reactivated upon subsequent
microbial exposure.
In spite of vaccines’ advantages for diseases control and prevention, three major limitations
related to vaccines are noted as follows:
1. Complex vaccination schedules
The potency of vaccines may not be high enough in receiving immunization only once.
Though the body develops antibodies, protection sometimes is not adequate due to the
development of immunity might be too slow to be effective in time. Furthermore, the
antibodies might not disable the pathogen completely, or there might be multiple strains
of the pathogen, not all of which are equally susceptible to the immune responses. In order
to provide the best protection, additional “booster” shots are often required to achieve
full immunity. Vaccine schedules are usually regulated by the competent authority or
physician groups to achieve maximum effectiveness. A vaccination schedule is a series of
vaccinations, including the timing of all doses, which may be either recommended or
compulsory. Many vaccines require multiple doses for maximum effectiveness, either to
produce sufficient initial immune responses or to boost responses that fade over time.
Over the past two decades, the recommended vaccination schedule has grown rapidly
and become more complex as many new vaccines have been developed.
2. Strict requirements for storage and shipment
Vaccines are temperature sensitive and their storage and shipment are usually restrict‐
ed to cold temperature [11]. Potency can be negatively affected by exposing to extended
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or multiple temperature excursions (out-of-range temperatures). It is essential to have a
label on the storage unit to indicate that vaccines should be stored in the freezer (−20 or
−80°C) or in the refrigerator (2–8°C). Correct cold-chain (a temperature-controlled supply
chain) procedures must be followed during production, warehousing, and transporta‐
tion, that is, vaccines have to be stored properly from the time that they are manufac‐
tured, distributed until administered to the people. Most live, attenuated vaccines tolerate
freezing temperatures, but deteriorate rapidly after being removed from cold tempera‐
ture. Inactivated vaccines will be damaged by exposing to temperature fluctuations. Cold-
chain failure has to be evaluated in addition to routine tests such as potency, sterility,
toxicity, safety, chemical, visual, and pyrogen test.
3. Restricted routes of administration
Most vaccine products are administered by injection such as intramuscular (IM), subcu‐
taneous (SC), and intradermal (ID) injection, though some can be given by oral adminis‐
tration or intranasal spray. IM injection administers the vaccine into the muscle mass.
Vaccines containing adjuvants should be injected into muscle to reduce adverse local
effects. SC injection administers the vaccine into the subcutaneous layer above the muscle
and below the skin. ID injection administers the vaccine in the topmost (dermis) layer of
the skin. BCG is the known vaccine with ID injection; this route reduces the risk of
neurovascular injury. The professional person’s assistance is usually required for the
injection administration. Oral administration vaccines (e.g., OPV and rotavirus vaccine)
make immunization easier by self-administration and eliminating the need of an injec‐
tor. The intranasal spray vaccine (e.g., influenza vaccine live) also offers a needle-free
approach through the nasal mucosa. Percutaneous administration, such as a multiple
puncture device (4–5 cm length, with 9 short needles) used for BCG vaccination in Japan,
indicates that any medical procedure is done via needle puncture of the skin, rather than
using an “open” approach where inner organs or tissues are exposed.
In the new era of subunit vaccines, to against both infectious diseases and cancers effectively,
subunits made of proteins, peptides, DNA antigens, or potent adjuvants may provide a good
choice to enhance immunogenicity. Subunit vaccines are not generally immunogenic in
humans because of size, degradation, destruction, nonspecific targeting, lack of cross-
presentation, and others [12]. This reveals that it is necessary to develop a new approach to
package and present antigens to the immune system. Nanomedicine is an area of research that
combines nanotechnology and medicine and provides new hopes for therapeutic strategies
and diseases control.
Advances in nanotechnology have shown to be beneficial for therapeutic strategies such as
drug discovery, drug delivery, and gene/protein delivery. Through nanotechnology, drug
consumption and side effects can be significantly decreased by locating the active agent at the
desired site. Nanotechnology is the study and application of extremely small things and
capable of being used in many science fields, such as biology, chemistry, physics, materials
science, and engineering. It is referred to the particular technology with a goal to precisely
manipulate atoms and molecules for fabrication of nanoscale products, which size below 100
nm (or sometimes up to 200–300 nm) [12] (Figure 2). Advances in nanotechnology in biome‐
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dicines have proved to be beneficial in vaccines development. The efficacy of vaccines can be
improved and side effects also can be significantly decreased. For the past decades, a nano‐
vaccine has become a novel approach for vaccination.
Adjuvants may be added to vaccines to modify the immune response by boosting it to give
more antibodies and longer-lasting protection. Adjuvants have been an important compo‐
nent of vaccine formulations since aluminum salt (Alum) was approved in the 1920s [13] and
adjuvant system 04 (AS04) was approved in 2009 in the United States, respectively. AS04 is a
trade name for combination of adjuvants used in vaccine products by GlaxoSmithKline (GSK),
which consists of aluminum hydroxide (Al (OH) 3) and 3-O-desacyl-4-monophosphoryl lipid
A (MPLA). The toll-like receptor (TLR) agonist and MPLA are being intensively investigated
as part of a new class of biological adjuvants [14]. In Europe, a few other adjuvants based on
oil in water emulsions such as adjuvant system 03 (AS03) and liposomes (made of lipid vesicles)
have been approved for using as adjuvants in humans by the European Medicines Agency
(EMA) since the 1990s [15]. AS03 is a trade name for a squalene-based immunologic adju‐
vant used in vaccine products by GSK, which contains squalene, DL-α-tocopherol and
polysorbate 80. For a great need for potent adjuvants in the vaccine clinical applications, we
believe that nanotechnology could be well positioned to take on such a challenge. Conse‐
quently, we focus on the vaccine products based on nanotechnology. In this chapter, we review
the regulation related to the development of nanovaccines, already marketed products based
on nanotechnology and the perspective of developing highly effective, stable, and economic
vaccines using micro-/nanoparticles.
Figure 2. Size comparison of biological substances: The size range of nanomaterials used in nanotechnology relative to
the size of various biological system. Abbreviation: virus-like particle (VLP).
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2. Regulation
In accordance with the guidelines of WHO, US Food and Drug Administration (FDA) and
EMA, vaccines belong to a heterogeneous class of agent; each has suitable, individual, and
specific standards of evaluation. The major quality concerns in a vaccine human clinical trial
are as follows:
1. Theoretical values and expected values of the trial: In preclinical studies stage, potency,
and immunogenicity should be tested in addition to toxicity and safety. A suitable animal
challenging model should be established; otherwise, an alternative method must be
proposed. The contribution and clinical significance of vaccine should be explained, and
a declaration of interest is usually needed.
2. Protection of the testers: The right and interest of testers should be emphasized either in
the placebo control group (e.g., use insert placebos) or the active control group (e.g., use
already licensed vaccines).
3. Selection of testing population group: Random health volunteers are tested in phase I, but
the representation of testers’ population should be considered in phase II and III. The
related factors include testers’ population, social economics, and the epidemiology of
target disease, etc.
4. Condition of inclusion and exclusion for testing population group: Tester should be in
good health condition and meet the criteria of examination, some people would be
excluded such as allergy, cardiovascular disease, immunodeficiency, and neuropathy
sicks.
5. Dosage, administration route, and schedule: Dose-response data should be achieved in
the dose-finding study. The schedule of vaccination depends on the traits of antigens, the
characteristics of testing population, and the pharmacokinetics induced by vaccines.
Tolerance, safety, dosage, and administration routes should be evaluated in phase I. The
optimal dose and schedule of vaccination should be defined in phase II and would be a
reference in phase III.
6. Safety evaluation of testers: The adverse events should be recorded and evaluated in all
phases of the clinical trial. Post-marketing surveillance for side effects in phase IV is
usually required.
7. Limitation of concomitant administration: The interaction between drugs and vaccines is
rare, but it is necessary to record the consequence while concomitant administering them.
8. Efficacy and effectiveness of vaccines: Vaccine efficacy is the measure of the reduced
disease incidence after vaccination, compared with the unvaccinated group. Vaccine
effectiveness is the measure of vaccine induced protection (not population related
protection), which is influenced with many factors such as the protection coverage of
vaccination, the immunological state of testers, and the epidemiology of target disease.
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9. Lot-to-lot consistency study: It is necessary to evaluate the consistency of vaccine
production and performance by comparing the different lots of vaccine products by the
predefined standard (usually various parameters in immunology).
Vaccines, as all medicinal products regulated by national regulatory authorities (NRA) and
national control laboratories (NCL), undergo a rigorous review of laboratory and clinical data
to ensure their safety, efficacy, purity, and potency. In the stages of discovery and develop‐
ment of vaccines, the manufacturer has to comply with the related regulation, including
nonclinical work, consultation, preclinical trials, and human clinical trials. Furthermore,
vaccines approved for marketing may also be required to perform additional studies to give
further evaluation and often address specific questions such as safety, efficacy or possible side
effects and contraindications for post-marketing surveillance (Figure 3).
Lot release is an independent assessment of each lot of a licensed vaccine or biologic prior to
it is released onto the market. General practices for lot release involve the review of manufac‐
Figure 3. Frame work of vaccine research and development: The research, development, surveillance, and application
of vaccines involve several practices performance and regulation requirements. (A) Stage: Vaccines discovery, devel‐
opment, and postmarked surveillance are three stages for the application of new vaccines. (B) Studies: There is much
research work to do at every stage. (C) Phase: Each stage can be divided into different phases. (D) Regulation: Various
regulations or guidelines are required for every stage. (E) Special procedure: fast track and communication. Abbrevia‐
tions: Good Laboratory Practice (GLP); Good Clinical Practice (GCP); Good Distribution Practice (GDP); Investigation‐
al New Drug (IND), Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme/
Good Manufacturing Practice (PIC/S GMP).
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turers’ production data and quality control test results by NRA and NCL. These practices can
be performed by an agency or a contracted laboratory for the NRA. It may be supplemented
by other documents such as the release certificate from the responsible NRA/NCL and in some
circumstances, by tests in the other laboratory which is independent of the manufacturers’
quality control testing.
Fast-track procedures can be implemented under special circumstances, such as disease
outbreaks or an acute shortage in global vaccine supply. It is a process designed to facilitate
the development and expedite the review of drugs that show promise in treating a serious or
life-threatening disease and address an unmet medical need as follows:
1. Serious condition: To determine if the drug will have an impact on such factors as survival,
day-to-day functioning or the disease will progress more serious if left untreated such as
acquired immune deficiency syndrome (AIDS), Alzheimer’s disease, heart failure, cancer,
epilepsy, depression, and diabetes.
2. Unmet medical need: The drug must be developed to treat or prevent a disease that does
not have a current therapy. If there are available therapies, a fast-track drug must show
some advantage over available therapy such as showing of superior effectiveness,
avoidance of serious side effects, improvement of the diagnosis, decrease of clinically
significant toxicity, and the need of emerging or anticipated public health.
The purpose of a fast-track designation is to get important new drugs to the patient earlier
through the consultation system. Once a drug receives fast-track designation, early and
frequent communication between the NRA and a drug manufacturer is encouraged through‐
out the entire development and review process of drugs. The communication ensures that all
questions and issues can be solved quickly, often leading to earlier drug approval and access
by patients. For example, US FDA is able to offer accelerated approval or priority review if the
requisite criteria are met. Priority review rapids the review process for a new drug from 6 to
10 months even can have US FDA make a final decision within 60 days.
In the application of nanoparticles as vaccines, some obstacles need to be overcome such as
stability during manufacturing and storage, sterilization by nonthermal methods, and
reproducibility of formulation during large-scale production [16]. Reproducibility of formu‐
lation during manufacturing is one of the major hurdles [17]; for instance, size-dependent
immunogenicity has been reported [18] and it is observed that nanomaterials may change
toxicity only by changing size and shape but not composition [19]. If the nanoparticles are
cleared slowly over a long period of time, they may induce toxic effect. In addition, large
counterparts may accumulate in vital organs to cause toxicity, even though small nanoparti‐
cles can be removed quickly from the body. Because of the toxic concerns of nanomaterials,
the potential effects on the human body, public health, and environment pollution should be
taken into account. It is necessary to evaluate the effects on DNA damage, gene expression,
cell death, and growth in the body when different types of cells are exposed to nanoparticles.
The safety surveillance and quality control of nanovaccines are as central as the evaluation of
their efficacy. Regulatory policies are based mainly on the purity and safety of the vaccine. For
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risk management, some special regulations or guidelines for nanotechnology application in
vaccines are as follows.
1. The approach to nanotechnology products
A. Product-focused and science-based regulatory policy
B. Attention to nanomaterials being incorporated into standing procedures
C. In legal standards for different product-classes
2. The regulation of pharmacopoeia (European Pharmacopeia 7.0 and 8.0; EP7.0, 8.0)
A. General provisions of products: The production method is validated to demon‐
strate that the product would comply with the test for abnormal toxicity for immu‐
nosera and vaccine for human use. Additionally, this method has to yield consistent
vaccines comparable with the vaccine of proven clinical efficacy and safety in
humans.
B. Preparation of nanoparticles (virosomes): Inactivated influenza virions are solubi‐
lized using a suitable detergent and purified by high-speed centrifugation to obtain
supernatants containing mainly influenza antigens. After the addition of suitable
phospholipids, virosomes are formed by removal of the detergent either by adsorp‐
tion chromatography or another suitable technique.
C. Tests of final products: residual infectious virus, pH, phospholipids, ratio of hemag‐
glutinin to phospholipids, antimicrobial preservative, free formaldehyde, ovalbu‐
min, total protein, sterility, virosome size, and bacterial endotoxin
3. Preclinical efficacy and toxicity testing of nanoparticles
A. Physicochemical characterization: size measurement, topology, molecular weight,
aggregation, purity, chemical composition, surface characteristics, functionality, zeta
potential, stability, and solubility test
B. In vitro characterization: sterility, targeting, drug release, in vitro immunology, and
toxicity test
C. In vivo characterization: efficacy and repeated-dose toxicity test
3. Products in the clinical application using micro/nanoparticles
Inflexal® V, Epaxal®, GardasilTM, and CervarixTM, marketed in many countries for over 10
years, are four common vaccine products based on micro/nanotechnologies. They use
nanoparticles-virosomes (special liposomes) or virus-like particles (VLPs) as a delivery and
adjuvant system, and all should be administered by IM and stored at 2–8°C (Table 2).
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Product Inflexal® V Epaxal® (1)GardasilTM and (2)CervarixTM
Indication Influenza Hepatitis A Cervical cancer
Formulation a mixture of three
monovalent virosome
pools
a vaccine adjuvanted
with IRIV
(1)Aluminum adjuvant
composed of AAHS
(2)AS04 adjuvant composed
of Al(OH)3 and MPLA
Nanoparticle Virosome Virosome VLP
Size in diameter 150 nm (100–300 nm) 150 nm (100–300 nm) 20–60 nm
Abbreviations: adjuvant system 04 (AS04); amorphous aluminum hydroxyphosphate sulfate (AAHS); aluminum
hydroxide (Al(OH)3); immunopotentiating reconstituted influenza virosomes (IRIV); 3-O-desacyl-4-monophosphoryl
lipid A (MPLA); virus-like particle (VLP).
Table 2. Comparison of different vaccine products based on nanotechnology.
A virosome is a kind of vaccine delivery tool with a typical size in diameter about 150 nm. It
consists of a phospholipid membrane vesicle incorporating viral-derived proteins and tends
to form a pure fusion-active vesicle. Virosomes are only able to fuse with target cells without
replicating inside their hosts. In contrast to liposomes, virosomes contain functional viral
envelope glycoproteins: influenza virus hemagglutinin (HA) and neuraminidase (NA)
intercalated in the phospholipid bilayer membrane. Virosomes represent an innovative,
extensively applicable adjuvant and carrier system and are used in areas beyond convention‐
al vaccines.
Virus-like particles (VLPs), derived from viruses and having no genetic materials, are self-
assembling nanoparticles (20–60 nm in diameter) that expose multiple epitopes on their surface
and resemble native virions [20, 21]. VLPs can differentiate themselves from soluble recombi‐
nant antigens, and their structure is capable of inducing stronger immune responses. They also
can express one or several viral structural proteins in a recombinant heterologous system [22],
for example, the recombinant baculovirus system results in the expression of massive and
various virus proteins. It is possible to engineer vaccines with multiple viral epitopes to elicit
protective immunity due to the availability of viral three-dimensional structures [23]. VLPs
co-administered with oil, mutant E. coli heat-labile toxins in calves [24] and with bluetongue
viruses in sheep [25] have provided protection against the related viruses. The immunogenic‐
ity of VLPs may be induced because of their interaction with dendritic cells (DCs) and has been
a useful approach for immunity against viruses in animals [16].
3.1. Inflexal® V
Influenza is an important respiratory infection of humans, responsible for many deaths
worldwide every year. The influenza viruses are genetic variable due to continuous and
gradual mutation as well as rearranged genome segments between viruses [26]. Frequent
mutations of the surface glycoproteins HA and NA result in the gradual evolution of viral
strains (antigenic drift). Consequently, it is required to develop a version of new influenza
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vaccine almost every year in that infectious viruses can no longer be neutralized effectively by
the antibodies raised against previously circulating strains.
Inflexal® V, an influenza vaccine, is composed of a mixture of three monovalent virosome
pools, each formed with specific glycoproteins HA and NA of one influenza virus strain. The
vaccine is completely biodegradable and contains no thiomersal, formaldehyde, and very low
levels of ovalbumin. Virosomes, reconstituted by nanotechnology, can deliver influenza
antigens to stimulate a strong immune response; thus, this product is highly efficacious by
mimicking natural viral infection [22]. The product has been approved by many countries and
is the only adjuvanted influenza vaccine licensed for all age groups.
3.2. Epaxal®
Hepatitis A is an acute infectious disease of the liver caused by the hepatitis A virus (HAV),
which symptoms include nausea, vomiting, diarrhea, jaundice, fever, and abdominal pain.
Around 10–15% of people experience a recurrence of symptoms during the six months after
the initial infection. Acute liver failure may rarely occur with this being more common in the
elderly.
Epaxal®, a hepatitis A vaccine, is adjuvanted with immunopotentiating reconstituted
influenza virosomes (IRIV). This vaccine is based on formalin inactivated HAV adsorbed to
the surface of virosomes that replace the adjuvant-aluminum hydroxide with phospholipids.
A single injection of virosomal HAV vaccine is well tolerated and highly immunogenic, with
88–97% of seroprotection 2 weeks after the first dose (reinforcing immunization: one dose at
6–12 months after the first dose).
3.3. GardasilTM and CervarixTM
HPV is a sexually transmitted infection and results in serious illness including genital warts
and cervical cancers. Cervical cancer is the second most common cause of cancer deaths in
females worldwide, only next to breast cancer [27]. HPV causes many cervical cancer cases
every year, of all the cases, type 16 and 18 are responsible for about 70%.
GardasilTM and CervarixTM are subunit vaccines containing VLPs assembled from the major
capsid protein (L1 protein) of HPV type 6, 11, 16, and 18 (GardasilTM) and type 16 and18
(CervarixTM) [21]. Vaccination with these two products has been shown to protect women
against a high proportion of precursor lesions of cervical cancer caused by HPV.
GardasilTM is a sterile liquid suspension prepared from the highly purified VLPs composed of
L1 proteins of HPV types 6, 11, 16, and 18. The L1 proteins of these HPV types (6, 11, 16, and
18) are produced by separate fermentations in the recombinant Saccharomyces cerevisiae and
self-assembled into VLPs. The VLPs for each type are purified and adsorbed on a aluminum-
containing adjuvant formulation-amorphous aluminum hydroxyphosphate sulfate (AAHS).
CervarixTM is a preparation of purified VLPs composed of L1 proteins of HPV type 16 and 18,
which is formulated in AS04 adjuvant-containing aluminum hydroxide and 3-O-desacyl-4-
monophosphoryl lipid A (MPLA) [28]. The MPLA immunostimulant is a detoxified deriva‐
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tive of the lipopolysaccharide of the bacterium Salmonella minnesota strain. The L1 proteins of
these HPV types (16 and 18) are separately produced using a recombinant baculovirus
expression system and the insect cell line derived from the moth-cabbage looper (Trichoplu‐
sia ni). After the expression of L1 proteins and further purification, L1 proteins are assem‐
bled separately as VLPs. It is the first vaccine licensed by the US FDA that includes MPLA as
an adjuvant. The adjuvant AS04 acts as a substance incorporated into a vaccine that enhan‐
ces or directs the immune response of the vaccinated individual.
The advantages that nanotechnology-based vaccines may over conventional vaccines are as
follows:
1. Substitution for traditional adjuvants: Nanovaccines demonstrated immunogenicity
similar to conventional vaccines without the presence of traditional adjuvant (Alum)
which is found to cause irritation.
2. Extended history of safety and shelf life: Nanoparticles as vaccine delivery systems avoid
the use of toxic substances such as thimerosal and formaldehyde and potentially extend
the stability of vaccines on the shelf.
3. Less frequency of administration for boost: Nanovaccines can be administered for
reinforcement immunization less frequently than conventional vaccines, which are
usually multi-injection or multi-dose delivery systems.
4. Perspective
Nanotechnology may provide us a new choice for safe and effective vaccines. However,
frequency of boost, refrigeration of vaccines, and routes of administration are still challenges
for vaccines distribution in small areas or villages of some countries. Nanovaccines are
expected to be more effective, convenient, and economic than conventional vaccines (Figure
4). We will have a great future ahead in nanovaccines if the following three aims are achieved.
1. Controlled release at specific location
Biodegradable polymers are superior to nondegradable polymers because the former may
not need additional removal procedures. For reliability and reproducibility, synthetic
biodegradable polymers are the best choice for antigen encapsulation in single-dose
vaccine production. Biodegradable polymer microsphere such as poly-1-lactic acid (PLA)
and poly lactic-co-glycolic acid (PLGA) has been used to control the time and rate of
vaccine antigen release due to their safety and ability to provide long-term controlled
vaccine antigen release [29]. Sustained release and pulsatile release are two possible types
of vaccine antigen release with biodegradable PLGA microspheres. Sustained release,
continued vaccine antigen diffusion after the initial release, mimics the administration of
several small boosters. Pulsatile release, second vaccine antigen diffusion distinct from
the first release, mimics the current vaccination schedule [30]. PLA and PLGA allow
encapsulation within a hydrophobic core or adsorption to the hydrophilic shell, which
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can manipulate to encapsulate vaccine within the interior [31, 32]. For example, tetanus
toxoid (TT) can be used to prevent tetanus which is caused by the bacterium Clostridium
tetani. A pattern of constant release with a decreasing release rate after the initial burst of
TT has been identified. Small-sized TT-PLA microspheres with rapid release kinetics
induced an earlier release compared with larger TT-PLGA 50:50 microspheres with slow
release kinetics [33]. A continuously increasing release rate after the initial burst was
observed with low molecular weight TT-PLGA microspheres [34].
Nanoscale carriers can enhance the potency of vaccines to develop safer and more effective
vaccine formulations. A nanoparticle-based strategy was demonstrated to safely deliver
and detain intact toxins to mount a potent anti-toxin immune response. A biomimetic
nanoparticle cloaked in biological membranes was used to sequester membrane-active
toxins. As the event of contacting with the nanoparticles, the toxins will retrained and lose
toxicity in that they are prevented from interacting with cellular targets. The resulting
particles and toxin complex adopts a nanoparticulate morphology that facilitates the
intracellular delivery of toxins. This technique assists to design a novel toxoid vaccine that
promises more effective anti-toxin immune responses. The potent nanotoxoid formula‐
tions provide a viable anti-virulence approach to combat with microorganisms that
contain membrane damaging toxins such as Staphylococcus aureus and Group A strepto‐
coccal infections [35].
2. Stable at room temperature
The common adjuvant -alum is known to cause irritation if it is used in the convention‐
al hepatitis B vaccine. However, the use of needle-free nasal immunization with a
combination of nanoemulsion and hepatitis B antigen was found to be tolerable, effec‐
tive, and safe without side effects [36]. The solvent extraction or evaporation from a water-
in-oil-in water (W/O/W) emulsion is usually used to prepare the antigen-encapsulated
nanoparticles [37]. Interestingly, refrigeration was not required for this nanoemulsion, as
it was effective at 25°C for one month and at 40°C for 6 weeks, respectively [16].
To make an effort to develop nanoparticles from biodegradable and biocompatible
polymers (e.g., PLA, PLGA) as vaccine delivery systems can induce both humoral and
cell-mediated immunity. These biodegradable polymers may make nanovaccines have
extended history of safety and proven biocompatibility at room temperature. The
additional advantage is their property to control the time and rate of polymer degrada‐
tion and antigen release [38].
3. Replaceable routes of administration
In addition to injection (IM, SC or ID), mouths and nostrils are two successful alterna‐
tive routes for administration. The vaccine can be given by these two routes without the
help of trained health workers and the equipment of sterile injection. These two meth‐
ods are relatively effective, inexpensive, and convenient, compared with injection. For
example, Sabin vaccine (OPV) and FluMist® are administered by oral administration and
intranasal spray, respectively, in contrast to Salk vaccine (IPV) and influenza vaccine
(flu shots), which are both given by injection.
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A. Sabin vaccine: An OPV is indicated for the prevention of poliomyelitis, which trivalent
contains a mixture of attenuated strains of three poliovirus types. The live polioviruses vaccine
produces antibodies to all types of poliovirus and triggers a local immune response in the
mucous membrane of the intestines. Once infected with wild polioviruses, these antibodies
protect against paralysis by restricting the viral replication inside the intestine to avoid
invading to the nervous system. Later, the live attenuated vaccine virus would be excreted in
Figure 4. Nanotechnologies applied in biomedicines’ vaccine (a cartoon figure for the perspective): Nanoparticles used
in the vaccine production potentially overcome the disadvantages of conventional vaccines. (A) Vaccines encapsulated
in nanoparticles which are polymers in solid form may be assistance in the stabilization at room temperature, elonga‐
tion of storage time, exploration of alternative administration routes, and facilitation of controlled release. (B) Nano‐
vaccines may only need to be boosted once; however, conventional vaccines usually need to be boosted many times.
(C) Soluble antigens released from nanovaccines may induce both humoral immunity (B cell responses) and cell-medi‐
ated immunity (helper and cytotoxic T cell responses). *Ab (antibody): serum immunoglobulin G (IgG), mucosal IgG
and mucosal IgA. Abbreviations: antigen (Ag); antibody (Ab); antigen presenting cell (APC); antibody forming cell
(AFC); antibody-dependent cytotoxic cell (ADCC); cytotoxic T cell (Tc); granulocyte (GC); helper T cell (Th); macro‐
phage (MAC); memory cell (MC); natural killer cell (NKC).
Micro and Nanotechnologies for Biotechnology100
the faces and spreaded to others in close contact. This means that OPV may result in the passive
immunization of unvaccinated people, so that OPV can rapidly stop person-to-person
transmission of wild poliovirus in areas where there is poor public health.
B. FluMist®: An intranasal spray attenuated vaccine is indicated for the prevention of influenza
which quadrivalent contains four virus strains (a type A/H1N1, a type A/H3N2, and two type
B strains). The live, attenuated influenza vaccine (LAIV) contains neither thimerosal nor
preservatives and is sprayed into the nostrils. LAIV produces a significantly stronger im‐
mune response than inactivated vaccines, because it is delivered via the natural site of entry
of the influenza virus [39–41]. In addition, this intranasal spray vaccine can prevent more 50%
cases than the flu shots given by IM in younger children [42].
The skin is also an attractive organ for vaccine delivery because of its large surface area that
is easily accessible for administration, and dermal delivery is almost pain-free [43, 44].
Furthermore, the skin contains many antigen presenting cells (e.g., Langerhans cells and
dermal dendritic cells) and is available for the induction of immune responses [44–46]. Besides,
the delivery via the skin circumvents the problem of swallowing, the first-pass effect of the
liver, and the absorption and stability of vaccines in the gastrointestinal tract. However, the
stratum corneum (the outermost layer of the epidermis) barrier may form significant resist‐
ance for vaccines to permeate into the body. To overcome the stratum corneum barrier,
percutaneous administration such as microneedle arrays (needle-like structures with a length
of less than 1 mm) [43–46] is one of the most promising delivery systems.
Microparticles or nanoparticles (e.g., PLA, PLGA) have been proved to be capable of making
an inactive Vibrio cholera whole-cell vaccine given by oral administration and demonstrating
in vitro release in mice [47]. This is an approach using nanoparticles as an oral delivery system
to improve bioavailability of vaccine and elated efficacy in therapy. Nanoparticulate materi‐
al makes it possible that vaccines can be given without invasion through oral, nasal spray, and
percutaneous administration such as diffusion patches, multiple puncture devices, and
microneedle arrays, thus allowing painless and efficient delivery without the involvement of
the professional.
5. Conclusion
Nanotechnology has extensively been utilized in the drug preparation and delivery for clinical
applications. Nanomedicine has already been an attractive research area and the develop‐
ment of nanovaccines is one of the most promising enterprises. A variety of nanoparticles in
vaccines have been employed as a delivery tool or immunity booster, inducing not only the
highest efficacy but also the least side effects. The significance of nanovaccine development is
to make it practical to have a perfect vaccination system including refrigeration-free, single-
dose, and painless administration. Indeed, we might have effective, safe, convenient, and
cheap vaccines through nanotechnology in the near future.
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